The penetration of ceftriaxone into the fetus at parturition was studied in 17 subjects. Despite its high protein binding, ceftriaxone quickly reached the umbilical cord blood, amniotic fluid, and placenta, achieving substantial concentrations, which then disappeared, with elimination half-lives of approximately 6 h, identical to that of the mother. The elimination half-life of ceftriaxone of 5 to 6 h in these mothers was somewhat shorter than that reported for normal subjects. The concentrations of ceftriaxone achieved in fetal tissues were sufficient for therapeutic effects. The penetration of ceftriaxone into milk was studied 3 days postpartum in 20 other patients. This antimicrobial agent entered breast milk rapidly and disappeared with a half-life of 12 to 17 h. The concentrations achieved were only 3 to 4% of those in maternal serum and were most likely of little clinical relevance.
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Broad-spectrum cephalosporins could prove to be highly useful for the prophylaxis or treatment of maternal or fetomaternal infections or both (9) . Since ceftriaxone has exhibited no serious toxicity in early use and since animal studies indicate no teratogenicity, one may anticipate the use of this drug in pregnancy (9) . We, therefore, investigated in 17 subjects the time course of the disappearance of ceftriaxone from the mother and its distribution into the umbilical cord blood, placenta, amniotic fluid, and urine of the neonate. In 20 additional subjects, we assessed the distribution into breast milk. (iv) Data analysis. The kinetic parameters of the penetration of ceftriaxone into milk were derived for individual subjects. The average values for these parameters were then calculated. Ceftriaxone distribution to the fetus was assessed by the analysis of semilogarithmic plots of average concentrations versus the time interval between the administration of ceftriaxone and delivery. The areas under the curve (AUC) of concentrations of ceftriaxone in serum, milk, amniotic fluid, and placenta were calculated by the trapezoidal rule without extrapolation to infinity (6, 12) .
MATERIALS AND METHODS
Except for the analysis of the AUC of the maternal serum concentrations of ceftriaxone after intravenous administration, the first datum was assumed to represent zero concentration at zero time, i.e., no lag time was incorporated. In quantifying the AUC in maternal serum after intravenous admhinistration of the drug, the first datum was the extrapolated y-intercept at zero time.
The half-life of the elimination of ceftriaxone from serum was calculated by least-squares linear regression of the logarithm of the serum concentration versus time, using the three data points. The half-lives of the disappearance from the umbilical cord serum, amniotic fluid, and placenta were determined by leastsquares linear regression of the terminal log-linear segments of plots of the logarithm of tissue concentration versus time. The kinetic parameters of ceftriaxone in maternal milk were quantified in each subject by nonlinear least-squares iterative fitting (NONLIN) (C. M. Metzler, G. L. Elfring, and A. J. McEwen, Biometrics 30:562, 1974), using the CSTRIP program to determine initial parameter estimates (13) . The data were fit to a one-compartment model of the format:
Where C is the concentration in milk at time t; A is a constant coefficient or intercept; and Kd and Ka are rate constants of elimination and absorption, respectively. The fitting of the data did not require the incorporation of a lag time.
RESULTS
Distribution of ceftriaxone to the fetus. The time course of the entry of ceftriaxone into the analyzed tissues and of its disappearance from them is shown in Table 1 , with derived parameters in Table 2 . Ceftriaxone reached substantial concentrations in the umbilical cord blood, amniotic fluid, and placenta by 1 h of sampling, peaked at 4 to 8 h, and was eliminated from all of these tissues with half-lives of approximately 6 h. The virtual identity of the elimination halflives from these tissues and those from maternal serum is striking.
The concentrations of ceftriaxone in the first voided urine of five of the newborns of these VOL. 23, 1983 voided into the amniotic fluid, the fetus may highly variable, ranging from 6 to then be redosed with the excreted drug, effectively limiting cumulative elimination. Similarly, iof ceftrlaxone into milk. The data just as the drug reaches the fetus from the graphically in Fig. 1 , with derived maternal circulation, the transfer undoubtedly Dtic parameters in Table 3 . The occurs in the opposite direction. The chemical im concentrations and the AUC in characteristics of the drug, such as protein bindpatients were approximately half ing, molecular size, lipid solubility, etc.; perfuubjects noted above, reflecting the sion relationships between mother and fetus; ller dose. Ceftriaxone entered and potentially a host of other factors can pre-[uickly and was then slowly elimi-sumably influence this bidirectional transfer nounts which gained entry, howev-(11). Since myriad determinants are undefined, 11 as reflected in the low concentra-it is virtually impossible to predict a priori the and the small AUC, approximately distribution of the drug to the fetus.
Le AUC of serum ceftriaxone conSince ceftriaxone may be used in pregnant ersus time. The concentrations of patients, we felt it important to explore its i milk after intramuscular adminis-distribution into fetal tissues and into milk. :onsistently higher than those after Although it was anticipated that the high protein binding (83 to 96%) of ceftriaxone would limit its transfer to fetal tissue, substantial and probably clinically relevant concentrations were attained in all samples assessed in this study ( 20 24 predictions with other drugs (1-5, 7, 8, 14) and TIME (hours) may be clinically important. However, because of uncertainty concerning the determinants of ceftriaxone in maternal serum and the fetomaternal transfer of drugs, the extrapolarsus time after intravenous (0) or intra-tion of our findings to chronic dosing with ceftridministration of a 1-g dose. Each group axone should be cautious until further studies ;ubjects.
specifically address this point. Since the majority of our patients received oxytocin to facilitate delivery, the possible effect of this drug should be considered. It is conceivable that this agent may influence the distribution of the drug to the fetus as has been shown to occur when prostaglandins have been used for therapeutic abortions (3) . Because of the substantial delivery that did occur to the fetus, however, a significant effect of oxytocin seems unlikely.
Because ceftriaxone is highly protein bound (9, 10), one might predict limited distribution out of maternal blood. Our finding of minimal penetration into breast milk is consistent with this postulate and similar to findings with cefotaxime (7) despite that cephalosporin's being considerably less protein bound (20 to 40%) (9) . In this single-dose study, the concentrations of ceftriaxone reaching breast milk were sufficiently low ( Fig. 1 ) that one would predict negligible clinical relevance save the possibility of altering the oral flora of the suckling infant. The prolonged elimination time of ceftriaxone from milk relative to that from maternal serum causes a disproportionate accumulation in milk with chronic dosing. Whereas steady-state maternal serum concentrations would be reached in approximately 1 
